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Abstract
Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus plat-
forms. However, efficient and sustained viral replication within tumours is limiting. Rapamy-
cin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and
mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were
shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0
(ICP0)-deleted HSV1 (HSV1-dICP0), we found that asTORi markedly augment infection in
cancer cells and a mouse mammary cancer xenograft. Mechanistically, asTORi repressed
mRNA translation in normal cells, resulting in defective antiviral response but also inhibition
of HSV1-dICP0 replication. asTORi also reduced antiviral response in cancer cells, however
in contrast to normal cells, transformed cells and cells transduced to elevate the expression
of eukaryotic initiation factor 4E (eIF4E) or to silence the repressors eIF4E binding proteins
(4E-BPs), selectively maintained HSV1-dICP0 protein synthesis during asTORi treatment,
ultimately supporting increased viral replication. Our data show that altered eIF4E/4E-BPs
expression can act to promote HSV1-dICP0 infection under prolonged mTOR inhibition.
Thus, pharmacoviral combination of asTORi and HSV1 can target cancer cells displaying
dysregulated eIF4E/4E-BPs axis.
Author summary
Dysregulated mRNA translation occurs frequently in tumours due to elevated eIF4E
expression or a hyperactive mTOR complex 1 (mTORC1) signaling pathway that results
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in the inactivation of the eIF4E binding proteins (4E-BPs). Targeting the mTORC1/4E-
BPs/eIF4E axis is a promising strategy in cancer therapies and for preventing resistance to
treatment. Enhanced mTORC1 activity also drives innate immune responses by modulat-
ing protein expression of antiviral genes. It was previously shown that the mTORC1
inhibitor rapamycin limits antiviral responses and promotes replication of oncolytic
viruses within tumour tissues. Active-site dual mTORC1 and mTORC2 inhibitors
(asTORi) have been developed for superior mTOR inhibition and anti-cancer potency but
have not been studied in the context of oncolytic viral infection. We show here that pro-
longed treatment with asTORi strongly augments infection of HSV1-dICP0 in cancer
cells, but not in normal cells, an effect modulated via eIF4E/4E-BP expression. Thus, can-
cer cells with dysregulated translation could be amenable to the pharmacoviral combina-
tion of HSV1 and asTORi treatment.
Introduction
Oncolytic viruses are promising immunotherapeutic agents for the treatment of cancer [1].
HSV1 application is amongst the most advanced and successful oncolytic platforms; with
Amgen’s oncolytic HSV1 talimogene laherparepvec (T-Vec, Imlygic) being the first oncolytic
virus to receive FDA and EMA (Food and Drug Administration and European Medicines
Agency) approval in October 2015 [2]. Numerous groups are developing oncolytic HSV1 vari-
ants, including the pre-clinical development of an infected-cell-protein-0-deleted HSV1
(HSV1-dICP0) [3]. Rapid viral clearance within tumour tissues constitutes a limitation for
oncolytic viral therapies. Thus, potentiating viral replication could further increase efficacy
[4].
We, and others reported that the drug rapamycin, an allosteric inhibitor of mTORC1, and
approved therapy for certain cancers, improves oncolytic viral replication within tumours
through suppression of innate immunity and type-I IFN production [5–7]. The protein kinase
mTOR, which integrates extra- and intracellular signals to affect cellular growth, proliferation,
metabolism, and survival, exists in two complexes: mTORC1, which is sensitive to rapamycin
and regulates mRNA translation, and mTORC2, which primarily controls actin cytoskeleton
organization [8]. Evidence for the role of mTORC1 signaling in innate immunity emerged
from the findings that rapamycin suppresses type-I IFN in plasmacytoid dendritic cells
(pDCs), which are the major producers of systemic type-I IFN [9]. Thereafter, it was shown
that silencing or chemically inhibiting upstream activators of mTORC1 compromises innate
immunity [5, 9–11], and that genetic deletion of the mTORC1 downstream targets ribosomal
S6 kinases (S6Ks) results in impaired type-I IFN response [5, 12]. Conversely, depletion of the
upstream mTORC1 repressors TSC1/2, or the absence of the translational repressors eIF4E-
binding proteins 1 and 2 (4E-BP1/2) downstream of mTORC1, leads to enhanced interferon-
regulatory factor 7 (Irf-7) mRNA translation and type I IFN production [13–16]. These studies
have highlighted the mTOR signaling pathway as a critical component of innate immunity by
controlling translation initiation of antiviral mRNAs [17].
Initiation of protein synthesis generally involves the recognition of the mRNA 5’-m7G-cap
structure by the eIF4F complex; consisting of eIF4E, a cap-binding protein; eIF4A, an RNA
helicase and eIF4G, a scaffolding protein that recruits eIF3 and the 40S ribosomal subunit to
the mRNA [18]. eIF4E can be sequestered from eIF4F by 4E-BPs; in conditions of mTORC1
inhibition, hypophosphorylated (activated) 4E-BP1/2, and inducible 4E-BP3, bind strongly to
eIF4E and repress translation, whereas hyperphosphorylated (inactivated) 4E-BPs do not,
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allowing formation of the eIF4F complex on the mRNA and initiation of protein synthesis [19,
20]. In cancer, mRNA translation is frequently dysregulated because of increased eIF4E pro-
tein levels and/or elevated phosphorylation of 4E-BPs due to a hyperactivated mTORC1 path-
way [21]. Targeting the aberrant mRNA translation in cancer represents an attractive strategy;
while the allosteric mTORC1 inhibitor rapamycin is a poor activator of 4E-BPs, ATP-competi-
tive active-site mTORC1 and 2 inhibitors (asTORi), are superior to rapamycin in inhibiting
mTORC1/2, activating 4E-BPs, and providing potent anti-cancer effects [22]. Interestingly,
the ratio of eIF4E to 4E-BPs was shown to determine the anti-proliferative efficacy of asTORi
[23, 24].
In contrast to rapamycin, which was previously reported to increase HSV1 infection in
some cancer cells [7], asTORi treatment strongly limits HSV1 replication in normal cells [25,
26]. Strikingly, while suppressing viral replication in normal fibroblasts and epithelial cells, we
observed that prolonged exposure to asTORi dramatically increases HSV1-dICP0 infection in
cancer cells. asTORi treatment results in reduction of type-I IFN responses in both cancer and
non-transformed cell lines, and strongly inhibits viral mRNA translation in normal cells. In
contrast, viral protein synthesis persists in cancer cells and cells transduced to either increase
eIF4E levels or deplete 4E-BP1/2, ultimately resulting in enhanced viral replication and spread.
Importantly, the combination of asTORi and HSV1-dICP0 reduces tumour size of an aggres-
sive syngeneic breast cancer mouse model. Thus, our data reveal that cancer cells harboring
altered mRNA translation via dysregulated eIF4E/4E-BPs axis can be targeted by the combina-
tion of asTORi and HSV1-dICP0.
Results
asTORi treatment enhances HSV1 infection of cancer cells, but suppresses
infection in non-transformed cells
Rapamycin augments the oncolytic potential of several viruses [5–7, 27–29]. asTORi are cur-
rently in clinical development [22, 30]. Therefore, we sought to determine whether the asTORi
PP242 and INK1341 could augment the infection of different oncolytic viruses in cancer cells.
The human glioblastoma cell line U251N or the mouse mammary carcinoma cell line 4T1
were infected with several oncolytic viruses including vesicular stomatitis virus (GFP-express-
ing VSVΔ51M), myxoma virus (GFP-expressing MV), vaccinia virus (GFP-expressing JX594)
and HSV1 (infected cell protein 0 (ICP0)-defective oncolytic HSV1 expressing GFP (HSV1-
dICP0)) in the presence or absence of asTORi. Our data showed that asTORi treatment limited
VSVΔ51M, MV, and vaccinia virus infection, but unpredictably strongly increased HSV1-
dICP0 infection and spread by 48 hours post-treatment (S1A–S1D Fig). This was unexpected
as it had been previously reported that asTORi strongly suppress wild type HSV1 infection of
primary human fibroblasts and primary mouse embryonic fibroblasts (MEFs) [25, 26]. To
address this conundrum, we infected primary human foreskin fibroblasts (HFF) and MEFs
with wild type HSV1 in the presence of rapamycin, or the asTORi PP242. As reported, wild
type HSV1 infection was repressed (more than 10-fold) by treatment with PP242 in normal
cells (Fig 1A). In stark contrast, this treatment markedly enhanced (5–10 fold) wild type HSV1
infection in the human glioblastoma cell lines U251N and HTB-14 (Fig 1B). Similar to
asTORi, rapamycin enhanced HSV1 infection in U251N (Fig 1B) and 4T1 cells (S1D Fig),
however unlike asTORi, rapamycin had only a partial effect in suppressing virus expression in
MEFs (Fig 1A).
We then examined the infection of various cancer cell lines with HSV1-dICP0 [3]. Support-
ing our data in U251N and 4T1 cells, asTORi (PP242, INK1341, INK128 or Torin1) treatment
increased HSV1-dICP0 infection and viral protein levels in multiple transformed human cell
mTOR inhibition and HSV1-dICP0
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lines (HEK293T, HCT116, Huh7) and mouse mammary tumour cell lines (4T1, NT2196) by
48–72 hours post-infection. In contrast, viral infection and protein synthesis were repressed in
several cell lines derived from normal tissues that were treated with asTORi: fibroblasts (MEF,
HFF), the non-transformed neuroblast cell line SHEP [31, 32], and the mouse epithelial mam-
mary cell line NMuMG (Fig 1C and 1D, S1E and S1F Fig and S2A–S2D Fig). To better
understand the kinetics of the enhanced viral infection in the presence of the asTORi PP242,
we used IncuCyte real-time imaging to monitor GFP-expressing HSV1-dICP0 in both the
NMuMG cell line and the NeuT-transformed NMuMG cell line NT2196 [33]. We found that
the increased GFP expression in the transformed NT2196 cells relative to DMSO-treated cells
begins only at 24 hours post-infection, and that asTORi strongly suppressed the virus in the
normal NMuMG cells (S1E Fig). Importantly, this effect was not unique to HSV1-dICP0, as
g34.5-deleted HSV1-1716, that has undergone clinical development [34], also led to an
increase in fluorescence upon treatment with PP242 as compared to DMSO control in the
Fig 1. Active-site mTOR inhibitors (asTORi) augment HSV1 infection specifically in transformed cells. (A) Primary mouse
embryonic fibroblasts (MEFs), human foreskin fibroblasts (HFF), and (B) human glioblastoma cell lines U251N and HTB-14 were
pretreated with DMSO, rapamycin (RAP 100nM), or the asTORi PP242 (2μM) for 30min followed by infection with wild type HSV1
at a MOI of 0.1 for 48 hours in presence of the inhibitors. Viral infection was monitored by Western blot using antibodies against
HSV1 antigens (top panel - 4E-BP1 and β-actin expression were used to monitor drug efficacy and loading, respectively), and plaque
titration (bottom panel—results are presented as titers normalized to DMSO control set at 100% ± SD (n = 3)). (C) Non-transformed
MEFs and HFF, as well as different transformed human cell lines, were infected with GFP-expressing HSV1-dICP0 for 48 hours at a
MOI of 0.1. Resulting infection was assessed by fluorescence microscopy. (D) Transformed (4T1 and NT2196) and non-transformed
(NMuMG) mouse mammary cell lines were pretreated with DMSO, rapamycin (100nM), PP242 (2μM) or INK1341 (100nM) for 30
min followed by infection with a GFP-expressing HSV1-dICP0 (0.1 MOI for 48 hours in presence of the inhibitors). Viral protein
synthesis was monitored by Western blot against HSV1. Drug efficacy was monitored by phosphorylation of rpS6 and 4E-BP1. Total
rpS6 and β-actin expression were used as loading controls.
https://doi.org/10.1371/journal.ppat.1007264.g001
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transformed NT2196 cell line (S1E Fig). However, the increase with g34.5-deleted HSV1-1716
was not as dramatic as seen with HSV1-dICP0. Furthermore, g34.5-deleted HSV1-1716 led to
no detectable GFP fluorescence in the normal breast epithelial cell line NMuMG. Therefore, to
characterize the differences between normal and transformed cells, we pursued experiments
primarily using HSV1-dICP0. By comparing 4T1 and NT2196 cells to NMuMG, we confirmed
that combining asTORi with HSV1-dICP0 potentiates viral infection (measured by Western
blot, GFP expression, and titration), and oncolysis (measured by crystal violet and trypan blue
exclusion) in the transformed mammary cells (Fig 1D, Fig 2A–2C, S1E and S1F Fig and S2E
Fig). Furthermore, intratumoural injection of luciferase-expressing HSV1-dICP0 in mice bear-
ing late-stage 4T1 tumours showed detectable luciferase expression only in tumours of mice
that had been administered asTORi (Fig 2D). Correspondingly, the combinatorial pharmacov-
iral treatment resulted in significant reduced tumour growth (by ~50% at day 18 post-implanta-
tion, p = 0.019 and p = 0.021 over PP242 or HSV1-dICP0 monotherapy respectively), and
moderately prolonged animal survival bearing this aggressive breast tumour as compared to
either pharmacological or viral single therapy (median survival 15 days post-treatment for the
combination compared to 8–10 days for PP242 or HSV1-dICP0 monotherapies, respectively,
Fig 2. asTORi specifically enhance HSV1-dICP0 oncolysis in transformed cells and tumours. Mouse mammary carcinoma cell lines
(4T1 and NT2196) and normal mammary epithelial cells (NMuMG) were pretreated with DMSO, rapamycin (RAP 100nM), PP242
(2μM) or INK1341 (100nM) for 30min followed by infection with GFP-expressing HSV1-dICP0 (0.1 MOI) in the presence of inhibitors.
At 48 hours post-infection, cell infection was monitored by (A) fluorescence microscopy, and at 96 hours post-infection, viability and
oncolysis were monitored by (B) crystal violet staining of live cells, and (C) trypan blue exclusion (represented as mean number of viable
cells ± SD normalized to respective mock infected control (n = 3)). (D-F) Luciferase-expressing HSV1-dICP0 infection is restricted to
tumour bearing mice treated with PP242. 4T1 cells were implanted subcutaneously in the right flank of syngeneic mice. Once tumours
were palpable (10 days post-implantation), mice were treated with PP242 (60mg/kg) or vehicle by gavage (days 10,12,14,17 and 18), and
injected or not with 107 pfu of FLuc-HSV1-dICP0 intra-tumourally (days 11 and 13) (n = 5 in each group). Luciferase expression was
measured by IVIS on day 14 (D). Size of tumours was monitored by electronic caliper (E), and overall survival was determined at end
point (F).
https://doi.org/10.1371/journal.ppat.1007264.g002
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p = 0.045) (Fig 2E and 2F). Collectively, these data demonstrate that mTOR inhibition by
asTORi suppresses HSV1 replication in non-transformed fibroblasts and epithelial cells (as pre-
viously reported [25, 26], but surprisingly the same treatment causes a robust, albeit delayed,
enhancement of HSV1 replication in cancer and transformed cells.
asTORi treatment reduces cellular type-I IFN responses
Inhibition of mTORC1 by rapamycin limits type-I IFN responses [5, 6, 9]. Additionally,
mTORC2 has been implicated in the regulation of innate immunity [35]. Thus, asTORi that
strongly impede the activation of both mTORC1 and 2, and potently activate 4E-BPs, are
expected to exhibit robust inhibition of type-I IFN production and antiviral responses in cells.
To assess whether asTORi treatment and activation (hypophosphorylation) of 4E-BPs limits
type-I IFN signaling, we transfected synthetic double stranded poly(I:C) RNA to mimic natu-
ral infection by viruses, or infected primary MEFs and the glioma U251N cells with wild type
HSV1 in the presence of rapamycin or the asTORi PP242. As previously reported [36, 37] and
shown above (Fig 1A and 1B), asTORi treatment resulted in complete dephosphorylation of
4E-BP1 in both MEFs and U251N cells, whereas rapamycin exerted only a partial effect on
4E-BP1 phosphorylation (Fig 3A and 3B, top panels). RT-PCR for Ifn-β after poly(I:C) RNA
transfection (Fig 3A and 3B, middle panels), or wild type HSV1 infection (S3A Fig), revealed
that cells treated with asTORi had limited induction of Ifn-β mRNA expression as compared
to rapamycin or DMSO control. Similarly, the ~4–5 fold increase in interferon-stimulated
response element (ISRE) promoter activity and type-I IFN production in presence of poly(I:C)
RNA was blocked in PP242-treated cells while a partial reduction was detected in rapamycin-
treated cells (Fig 3A and 3B, bottom panels). Using conditioned media from MEFs or U251N
cells treated with poly(I:C) RNA and DMSO (control), rapamycin, or asTORi, a reduced pro-
tection from subsequent wild type HSV1 infection was primarily observed in asTORi treated
cells (Fig 3C and S3B Fig). Similarly, RT-PCR for HSV1 gC transcripts and ISRE reporter
activity from the human glioblastoma HTB-14 cells infected with wild type HSV1, confirmed
that PP242 treatment limits the induction of ISRE reporter activity, with a corresponding
increase in HSV1 gC transcript levels (Fig 3D). Furthermore, the induction of Ifn-β mRNA
levels measured by RT-qPCR was suppressed to a similar extent upon asTORi treatment and
HSV1-dICP0 infection in 4T1, NT2196, and NMuMG cells (Fig 3E). Additionally, the inhibi-
tory effect of asTORi on type I IFN production was maintained in poly(I:C)-stimulated normal
human foreskin fibroblasts HFF and human glioblastoma cell lines U343 and U373 (S3C Fig).
To further demonstrate that dual mTORC1/2 inhibitors impair the innate immune response,
we performed polysome profiling and translation reporter assays of cellular and viral mRNAs.
These experiments showed that Irf7 mRNA is excluded from polysomes in 4T1 and NT2196
cells infected with HSV1-dICP0 in the presence of the asTORi PP242 (S3D–S3G Fig). In con-
trast, the interferon-induced gene Isg15 was rather weakly induced transcriptionally upon
asTORi treatment as compared to control (S3G Fig). Importantly, these experiments also
demonstrated that HSV1-dICP0 viral mRNAs (ICP4, gC, TK) are highly transcribed and more
abundant in polysome fractions when 4T1 or NT2196 cancer cells were treated with asTORi as
compared to DMSO control (S3E–S3G Fig). To examine the translational repression of Irf7
mRNA versus HSV1 genes, we generated reporter constructs by merging the 5’ UTR of Irf7, or
those of HSV1-TK or ICP0, to a luciferase reporter gene, and measured luciferase expression
upon DMSO (control) versus asTORi treatment in 4T1 cells. TK and ICP0 were selected since
they have well annotated 5’ UTR that could be readily cloned into our reporter system. As
expected from previous data using the asTORi Torin1 or silencing of eIF4E [38], these experi-
ments showed that the reporter construct containing the 5’ UTR of Irf7, which is highly
mTOR inhibition and HSV1-dICP0
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structured [14], was repressed translationally, in contrast to the reporter constructs containing
the ICP0 or the TK 5’ UTR (S3H Fig). These results demonstrate that mTORC1/2 inhibition
by asTORi strongly limits innate antiviral responses and production of type-I IFN in both nor-
mal and cancer cells.
asTORi treatment represses host and viral protein synthesis in normal
cells, but viral mRNA translation persists in cancer cells
Our results show that asTORi treatment suppresses type-I IFN signaling in both normal
fibroblast/epithelial cells and cancer cell lines. To determine whether early infection of
Fig 3. asTORi suppress cellular type-I IFN responses. Non-transformed mouse embryonic fibroblasts (MEFs) (A), or the
human glioma cell line U251N (B) were transfected with 1μg/ml poly(I:C) RNA in the presence of DMSO, rapamycin (RAP
100nM) or PP242 (2μM). mTORC1 inhibition was monitored by assessing the phosphorylation status of 4E-BP1 by Western
blot (A and B top). Ifn-β transcript levels were measured by RT-PCR (A and B middle), and type-I IFN responses were
measured using ISRE reporter activity assay (A bottom), or HEK-Blue type-I IFN assay (B bottom), presented as fold change
compared to untreated control cells set to 1 ± SD (n = 3). (C) Protection assay, MEFs or U251N cells were transfected with
1μg/ml poly(I:C) RNA and treated as in (A,B). The supernatant collected 24 hours later was used to condition “naïve” MEFs
or U251N cells for 6 hours followed by wild type HSV1 infection for 24 hours. Viral replication in the conditioned cells was
monitored by Western blot (C top) and plaque assay titration (C bottom–results are presented as titers normalized to DMSO
control set at 100% ± SD (n = 3)). (D) HTB-14 cells were transfected with an ISRE reporter and infected with wild type HSV1
at 1 MOI in the presence of DMSO or increasing concentrations of PP242. Concomitant luciferase counts of ISRE reported
activity (presented as fold change over mock control set to 1 ± SD (n = 3)) and wild type HSV1 gC transcripts levels were
monitored by luciferase assays and by RT-PCR, respectively. (E) Transformed 4T1 and NT2196 cells, as well as non-
transformed NMuMG cells, were treated with DMSO or INK1341 (100μM) and infected with GFP-expressing HSV1-dICP0
(0.1 MOI) for 24 hours. Ifn-β mRNA levels were measured by RT-qPCR. Results are presented as fold change normalized to
DMSO control set to 1 ± SD (n = 3).
https://doi.org/10.1371/journal.ppat.1007264.g003
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HSV1-dICP0 was accelerated by asTORi treatment, we assessed the mRNA levels of the imme-
diate early viral gene ICP4 at 8 hours post-infection in 4T1, NMuMG and NT2196 cells treated
either with DMSO or the asTORi INK1341. RT-qPCR data revealed no significant changes in
ICP4 mRNA levels between the conditions used for all cell lines, suggesting that viral entry was
generally not affected by asTORi treatment (S4A Fig). Therefore, we reasoned that the specific
augmentation of HSV1-dICP0 replication in cancer cells cannot be explained by either a more
pronounced reduction in type-I IFN responses, or an increase in viral entry. Protein synthesis
is frequently dysregulated in cancer and contributes to resistance to therapeutic drugs, particu-
larly mTOR inhibitors, by allowing the continued translation of a subset of mRNAs involved
in cell proliferation [23, 24, 37]. Interestingly, a recent report demonstrated that transient fast-
ing, a condition that causes reduced mTORC1 activity, enhances the replication of oncolytic
HSV1 in glioblastoma cells, which was proposed to be mediated by dysregulated protein syn-
thesis in cancer cells [39]. We examined global protein synthesis by supplementing with [35S]-
Met in the growth media of 4T1, NT2196 and NMuMG cells infected with HSV1-dICP0 and
treated with the asTORi PP242. PP242 and HSV1-dICP0 treatment resulted in reduction of
global protein synthesis, an effect that was more pronounced and sustained in NMuMG cells
as compared to the transformed 4T1 and NT2196 cell lines (~50% [35S]-Met incorporation
over DMSO control for NMuMG, versus ~70% and 85% for 4T1 and NT2196, at 24 hours
post-infection respectively) (Fig 4A). As previously observed for early time points post-infec-
tion in cancer cells (S1A and S1E Fig), HSV1-dICP0 protein levels at 24 hours post-infection
were comparable in control (DMSO) and PP242-treated 4T1 and NT2196 cancer cells, but
were barely detected in the normal epithelial cell line treated with PP242 (Fig 4A). In agree-
ment with the [35S]-Met incorporation results, polysome profiling analyses showed that PP242
treatment engendered a stronger reduction in polysomal RNA in NMuMG cells than in 4T1
and NT2196 cell lines (Fig 4B). PP242 treatment also reduced [35S]-Met incorporation to a
higher extent in HFF as compared to U251N, and suppressed wild type HSV1 protein expres-
sion only in HFF (S4B Fig). Interestingly, PP242 inhibited HSV1-dICP0 protein expression in
the non-transformed NMuMG cells at low concentrations (0.4–0.6μM), while exerting the
opposite effect on transformed NT2196 cells up 2μM. However, higher concentrations of
asTORi ultimately reduced HSV1-dICP0 infection in certain cancer cell lines (S4C and S4D
Fig), suggesting that excessive mTOR suppression can limit HSV1-dICP0 protein synthesis
and concomitant infection. These data indicate that asTORi treatment induces a stronger and
more sustained translational repression in normal cells than in cancer cells, which ultimately
dampens efficient HSV1 protein synthesis and replication. Transformed cells maintain higher
levels of protein synthesis under asTORi treatment, recover more quickly, and sustain HSV1
mRNA translation thereby promoting the replication of the virus.
asTORi-dependent augmentation of HSV1-dICP0 propagation is altered
by modulating eIF4E/4E-BP expression
The ratio of eIF4E/4E-BP protein expression determines the anti-proliferative efficacy of
mTOR inhibitors [23, 24, 37, 40]. Elevated eIF4E expression, in relation to 4E-BP1/2/3, ren-
ders cells more resistant to the repression of proliferation and mRNA translation by asTORi.
Interestingly, asTORi inhibition of wild type HSV1 in MEFs was previously shown to be
dependent on 4E-BP1 expression [26]. Therefore, we hypothesized that dysregulated protein
synthesis due to altered eIF4E/4E-BP ratio in cancer cells is responsible for the differences in
HSV1-dICP0 infection between normal and cancer cells treated with asTORi. Initially, we
sought to compare the ratio of eIF4E to 4E-BPs in normal and transformed mouse mammary
cells lines. While eIF4E and 4E-BP1 protein expression appeared similar between these cells,
mTOR inhibition and HSV1-dICP0
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the normal NMuMG cell line exhibited higher expression of 4E-BP2 (and a slight increase of
4E-BP3 upon mTOR inhibition) in comparison to the transformed 4T1 and NT2196 (S4E
Fig). To test the hypothesis that elevated eIF4E or reduced 4E-BPs protein expression contrib-
utes to HSV1-dICP0 viral propagation in the presence of asTORi, we transduced 4T1,
NT2196, and NMuMG cells with constructs expressing V5-tagged eIF4E, 4E-BP1 or the con-
trol Blue Fluorescent Protein (BFP). Strikingly, V5-4E-BP1 overexpression (i.e. reduced
eIF4E/4E-BP1 ratio) prevented the asTORi-mediated increase of HSV1-dICP0 protein synthe-
sis in transformed cells (4T1 and NT2196), and resulted in greater repression of HSV1-dICP0
infection by asTORi in normal cells (NMuMG). In contrast, eIF4E overexpression in the
NMuMG cells led to sustained viral protein synthesis during asTORi treatment (Fig 5A and
5B).
To confirm the contribution of the eIF4E/4E-BP axis in potentiating HSV1-dICP0 infection
during asTORi treatment, we knocked down eIF4E, 4E-BP1 or 4E-BP2 in 4T1, NT2196 and
Fig 4. The asTORi PP242 suppresses host and viral protein synthesis in normal cells but sustains HSV1-dICP0 protein synthesis in
cancer cells. (A) 4T1, NMuMG and NT2196 cells were infected in triplicates with GFP-expressing HSV1-dICP0 (0.1 MOI) in the presence
of DMSO or PP242 (2μM), pretreated for 30 min prior to infection. Global protein synthesis was assessed by a 30 min pulse [35S]methionine
incorporation into newly synthesized proteins at 2 hours and 24 hours post-infection. Triplicate cell lysates were separated on SDS-PAGE
and changes in protein synthesis were revealed by autoradiography (top), [35S]methionine incorporation was measured by TCA
precipitation and quantified on scintillation counter (middle–results presented are normalized to DMSO control set to 100% ± SD (n = 3)),
and 4E-BP1 phosphorylation status as well as the levels of HSV1 proteins were assessed by Western blot (bottom). (B) Polysome profile
analysis of 4T1, NMuMG and NT2196 cells treated and infected with HSV1-dICP0 as above for 24 hours.
https://doi.org/10.1371/journal.ppat.1007264.g004
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NMuMG cells. Silencing eIF4E led to a strong repression of HSV1-dICP0 infection in cancer
cells treated with asTORi, while silencing 4E-BP1 or 4E-BP2 had a reverse effect (Fig 6A and
6B and S4F Fig). To examine this response in other cell models, we used NIH3T3 mouse
fibroblasts that overexpress eIF4E [41]. PP242 treatment in non-transformed control NIH3T3
cells limited wild type HSV1 infection. However, transformed NIH3T3 cells with excess levels
of eIF4E were resistant to PP242-mediated suppression of wild type HSV1 protein expression
(S5A Fig). Similar results were obtained using the non-transformed human neuroblast cell
line SHEP [31, 32], where PP242 treatment decreased wild type HSV1 protein levels in cells
treated with empty vector control, but not in cells overexpressing eIF4E (S5B Fig). As
expected, a stronger suppression of wild type HSV1 protein expression was also observed in
SHEP cells overexpressing 4E-BP1 (S5C Fig). Consistent with these findings, silencing eIF4E
or increasing expression of 4E-BP1 in U251N cells diminished the elevated infection of
HSV1-dICP0 in presence of asTORi, whereas eIF4E overexpression had the reverse effect
(S5D–S5H Fig). These data demonstrate that cells with overexpression of eIF4E or reduced
expression of 4E-BPs, can sustain HSV1 protein synthesis during mTOR inhibition. The
results further support the notion that in cancer cells with dysregulated eIF4E/4E-BP ratio,
administration of asTORi could promote the replication of HSV1-dCIP0.
Fig 5. Overexpression of eIF4E or 4E-BP1 modulates the effects of asTORi treatment on HSV1-dICP0 infection. Transformed 4T1 and
NT2196 and non-transformed NMuMG were transduced to stably overexpress V5-tagged eIF4E, 4E-BP1, or control (blue fluorescent protein
—BFP). Transduced cells were infected with GFP-expressing HSV1-dICP0 (0.1 MOI) in the presence of DMSO, PP242 (2μM), or INK1341
(100nM), pretreated for 30 min prior to infection. At 48 hours post-infection, virus protein synthesis and infection were monitored by (A)
Western blot and (B) fluorescence microscopy. Expression of V5-tag, eIF4E and 4E-BP1 showed drug efficacy and protein overexpression. β-
actin was used as loading control.
https://doi.org/10.1371/journal.ppat.1007264.g005
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Discussion
In this study we investigated the pharmacoviral combination of asTORi and HSV1-dICP0.
asTORi treatment suppressed type-I IFN responses in normal and cancer cells. The treatment
impaired the replication of HSV1-dICP0 in non-transformed cells, but infection was strikingly
augmented in cancer cells. Furthermore, in an aggressive syngeneic mammary cancer mouse
model, the combination of asTORi and HSV1-dICP0 reduced tumour size and prolonged sur-
vival compared to either monotherapy. Mechanistically our data show that asTORi treatment
initially represses global mRNA translation, but HSV1-dICP0 protein expression persists in
cancer cells and cells with dysregulated eIF4E/4E-BP ratio. Since cancer cells with high eIF4E
expression demonstrate resistance to the anti-proliferative effects of asTORi [23], combining
dual mTORC1 and 2 inhibitors with HSV1-dICP0 could potentially provide the selective
advantage of increasing viral oncolysis of mTOR-inhibitor resistant cancer cells.
The eIF4E/4E-BP1 ratio is a key determinant of cell response to mTOR inhibitors as
tumour cells with a high eIF4E/4E-BP1 ratio exhibit low sensitivity to asTORi-induced cell
proliferation arrest [23, 24, 37]. Furthermore, in hepatocellular carcinoma cells or aggressive
B-cell lymphomas, high eIF4E/4E-BP1 confers resistance to metformin-induced apoptosis or
mTOR inhibitors, respectively [24, 40]. In addition, the mTORC1 signaling pathway is often
hyperactivated in cancer resulting in elevated phosphorylation of 4E-BPs [21]. mTORC1 activ-
ity was previously demonstrated to be required for wild type HSV1 infection and replication as
primary human and mouse fibroblasts treated with asTORi were resistant to wild type HSV1
infection [25, 26]. Interestingly, Moorman and Shenk showed that primary MEFs depleted of
Fig 6. Silencing eIF4E or 4E-BP1 modulates the effects of asTORi treatment on HSV1-dICP0 infection. Transformed 4T1 and
NT2196 and non-transformed NMuMG were transduced to stably express shRNA against eIF4E, 4E-BP1, or scrambled shRNA control.
Transduced cells were infected with GFP-expressing HSV1-dICP0 (0.1 MOI) in the presence of DMSO, PP242 (2μM), or INK1341
(100nM), pretreated for 30 min prior to infection. At 48 hours post-infection, virus protein synthesis and infection were monitored by (A)
Western blot and (B) fluorescence microscopy. Expression of eIF4E and 4E-BP1 showed drug efficacy and target knockdown. β-actin was
used as loading control.
https://doi.org/10.1371/journal.ppat.1007264.g006
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4E-BP1 produced equal yields of HSV1 in the presence or absence of asTORi [26]. We also
report here that asTORi treatment potently repressed wild type HSV1 and HSV1-dICP0 in
several normal cell lines, but found that viral replication and spread is markedly augmented
under prolonged asTORi treatment within cancer cells. We further show that varying the cel-
lular expression levels of eIF4E, 4E-BP1 or 4E-BP2 results in differential HSV1-dICP0 infectiv-
ity in the presence of asTORi. Notably, forced expression of eIF4E was recently reported to
strengthen the potency of oncolytic measles virus [42]. Since wild type HSV1 infection is
known to stimulate mTORC1-dependent 4E-BP1 inactivation [25], our results suggest that
dysregulated eIF4E/4E-BP ratio and/or hyperactivated mTORC1 in cancer cells contribute to
sustain, and ultimately favor viral protein synthesis in the presence of asTORi over antiviral
mRNA translation. This model is consistent with previous data showing translation of antiviral
Irf7 mRNA to be highly sensitive to 4E-BPs [14–16], and to asTORi treatment as presented
here. Nonetheless, it is noteworthy that overexpression or silencing of eIF4E in cells can induce
a compensatory response vis-a-vis 4E-BP1/2 expression or 4E-BP1 phosphorylation [23, 43].
We did observe changes in expression and phosphorylation of 4E-BP1 upon altering the levels
of eIF4E in the transduced cells treated with asTORi. This compensatory mechanism may
have impacted partly on the replication of HSV1-dICP0.
Recently, short-term fasting was shown to enhance oncolytic HSV1 replication in glioblas-
toma cell lines and tumours; critically, this was not observed in normal astrocytes [39]. 4E-BP1
phosphorylation was sustained during fasting in the glioblastoma cell lines, which was not the
case in normal astrocytes [39], highlighting a resistance to mTORC1 inhibition and translation
repression phenotype in transformed cells, similar to that described here. High eIF4E versus
4E-BP expression is suggested as a cancer prognosis measure [44], and we have shown that
tumour samples of patients with hepatocellular carcinoma exhibit variable eIF4E/4E-BP1
ratios [24]. Thus, it is plausible that certain types of tumours could be selectively targeted by
the pharmacoviral approach of dual mTORC1/2 inhibition and oncolytic HSV1. In addition,
our results suggest that alterations in the mRNA translation machinery, in the context of ele-
vated eIF4E or decreased 4E-BP expression, can promote HSV1 infection in the presence of
asTORi (S6 Fig).
In our study we used an ICP0-deleted HSV1 that has been investigated and developed as an
oncolytic virus platform but that has not been translated to the clinic [3, 45–47]. A limitation
of our study is that the oncolytic HSV1 platforms that have progressed to clinical trials are at-
tenuated through gamma34.5 (g34.5) gene deletion. Using the clinically relevant g34.5-deleted
HSV1-1716 [34], we have observed a similar augmentation of viral infection by asTORi treat-
ment in the transformed NT2196 cell line. Nonetheless, additional experiments with g34.5-
deleted HSV1 are necessary to fully address the clinical implications of the findings presented
here. Furthermore, oncolytic HSV1 research is now focused on improving immunotherapeutic
anti-tumour responses, and the virus is administered together with checkpoint inhibitors in
clinical trials [48]. Finding the right balance of immunosuppression during delivery of the
oncolytic virus (to minimize innate antiviral responses) while retaining the humoral immunity
required for an efficient and durable anti-tumour response will prove challenging. Indeed,
“pre-conditioning” with the immunosuppressive drug cyclophosphamide during viral delivery
has been shown to increase viral loads in several pre-clinical studies and early-phase trials [49].
However, this regimen may not elicit potent anti-tumour immune responses. Another concern
is that asTORi treatment can reactivate latent HSV1 infections, the sequelae of which could
complicate patient outcomes. This has been observed in a latently infected neuron culture
model [50] as well as in organ transplant patients treated with immunosuppressive agents
including mTOR inhibitors [51]. Despite these concerns, augmenting the initial phase of viral
replication specifically within tumour tissues, either through transient systemic or localized
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intra-tumoural mTOR inhibitor therapy, could provide the added benefit of reducing cancer
cell proliferation and inducing a subsequent increase in viral replication, which upon drug
removal could elicit a more potent therapeutic immune response [52]. Such transient or
tumour-targeted mTOR inhibition would need to be investigated in additional immune-com-
petent cancer animal models to determine the correct dosing and its potential therapeutic effi-
cacy in combination with oncolytic HSV1.
Finally, other complementary pathways (e.g. MEK/ERK and MNK/eIF4E phosphorylation)
can become activated during prolonged mTOR inhibition or upon infection by viruses [21, 53,
54]. While we did not assess the contribution of these alternative signaling cascades here, addi-
tional studies are required to investigate their functions in cellular and HSV1 mRNA transla-
tional control during mTOR inhibition. In conclusion, we have shown that asTORi treatment
induces a cellular state in transformed cell lines or cells exhibiting a dysregulated eIF4E/
4E-BPs axis that HSV1 usurps for increased replication.
Materials and methods
Cell lines, viruses, and mTOR inhibitors
The human cell lines: foreskin fibroblast HFF, transformed embryonic kidney HEK293T,
malignant glioblastomas U251N and HTB-14, hepatocellular carcinoma Huh7, the non-trans-
formed neuroblasts SHEP, and colon carcinoma HCT116 were obtained from ATCC and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM-Wisent) supplemented with 10% fetal
bovine serum (Wisent) and 100 units/ml Penicillin-Streptomycin (Wisent). The transformed
murine mammary gland cell line 4T1 (ATCC) was propagated in Roswell Park Memorial
Institute medium 1640 (RPMI1640-Wisent) supplemented with 10% fetal bovine serum and
100 units/ml Penicillin-Streptomycin. The normal murine mammary gland cells NMuMG
and the NeuT transformed NMuMG, NT2196, described in [33] were generously provided by
Dr. William J. Muller. Both cell lines were cultured using the same DMEM medium as before
but with the addition of 10mM HEPES pH7.5 (Wisent) and 10μg/ml insulin (Wisent).
NT2196 medium was also supplemented with 1μg/ml puromycin (Bioshop). The mTOR
inhibitors Rapamycin, PP242, and Torin1 were purchased from Sigma, INK1341 and INK128
were obtained from Intellikine INC, as previously described in [23, 55]. TRCN0000468751
(pLX317 EIF4EBP1) and TRCN0000471416 (pLX317 eIF4E) lentiviral vectors from the MIS-
SION TRC3 Human LentiORF Collection (Sigma) were used to generate cells stably over-
expressing wild type human eIF4E or 4E-BP1. 4E-BP1/2 and eIF4E shRNA vectors were previ-
ously described [23]. Wild type Herpes simplex virus 1 (HSV1) KOS strain, GFP-expressing
HSV1-dICP0 mutant and FLuc-expressing HSV1-dICP0 have been previously described [3].
The wild type HSV1 and HSV1-dICP0 were propagated and titered on Vero cells, following
purification and concentration via sucrose cushion ultracentrifugation. The GFP-expressing
HSV1-1716 was provided by Virttu Biologics, UK / Sorrento Therapeutics, San Diego, USA.
Western blot analysis
Cells were washed with ice-cold PBS and lysed on ice using RIPA buffer (50mM Tris-HCl pH
8.0, 150mM NaCl, 0.1% SDS, 0.5% Sodium deoxycholate, 1% Triton X100, 10mM Sodium
Fluoride, 1mM Sodium orthovanadate, 1mM DTT and protease inhibitor cocktail (Roche)).
Cell debris were removed by centrifugation at 10,000g for 10min at 4˚C. Protein concentration
was determined using BioRad assay. Herpes Simplex Virus Type 1 polyclonal antibody was
purchased from Dako (Agilent Technologies), total 4E-BP1, 4E-BP2, phospho-S240–S244
rpS6 antibodies were from cell signaling, total rpS6 and alpha-tubulin antibodies were from
Santa Cruz, eIF4E antibody was from BD Biosciences, β-actin antibody was from Sigma and
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V5-tag antibody was from Life Technologies. Anti-4E-BP3 number 1791 was previously
described [20].
ISRE-promoter and HEKBLUE (human) type-I IFN assay
The plasmids encoding the ISRE promoter linked to firefly luciferase and Renilla luciferase
(transfection control) were transfected using Lipofectamine and Plus reagent (Invitrogen)
according to the manufacturer’s instruction. Cell extracts were prepared in 1X passive lysis
buffer (Promega) 48 hours post-transfection and assayed for RLuc and FLuc activity in a
Lumat LB95507 bio luminometer (EG and G Bertold) using a dual-luciferase reporter assay
system (Promega) according to the manufacturer’s instructions. FLuc activity was normalized
against RLuc activity. For the HEKBLUE assay, cells were transfected with 1μg/ml poly(I:C)
(InvivoGen) using lipofectamine 2000 (Life Technologies) as per manufacturer’s instructions.
Type-I IFN-containing supernatant was collected 24 hours post-transfection. HEKBLUE cells
were seeded into a 96well plate (50,000 cells per well), mixed with 20μl of supernatant for a
total volume of 200μl per well and incubated overnight to allow for the expression of Secreted
Embryonic Alkaline Phosphatase (SEAP). To quantify the levels of IFN-induced SEAP, 160 μl
of Quanti-Blue (InvivoGen) were mixed with 40μl of supernatant and incubated at 37˚C for
30min. The absorbance of the resulting reaction was measured at 650nm.
Cell viability and live cell monitoring of virus spread
NMuMG, NT2196 and 4T1 cells were infected at the indicated multiplicity of infection for 96
hours after which cells were fixed using 20% TCA solution for 5min and stained with crystal
violet for 30 min followed by gentle wash with distilled water. Crystal violet stock solution was
prepared by dissolving 1g of crystal violet in 100ml of 20% ethanol. Working solution prepared
by mixing 20ml of the stock solution with 40ml of 100% ethanol and 140ml of distilled water.
For quantification purposes, remaining viable cells from a separate experiment were manually
counted using a hemacytometer and Trypan Blue exclusion. Live cell monitoring of virus
spread was measured using the IncuCyte ZOOM system (Essen BioScience, MI, US).
NMuMG and NT2196 cells were seeded at 80–90% confluency and were pretreated with
DMSO or PP242 prior to infection at the indicated MOI. Multiple images per well were taken
every 2 hours until the predermined end point. Images were then analyzed using the IncuCyte
ZOOM software (Essen BioScience, MI, US) to calculate for the GFP cluster integrated inten-
sity (Green calibrated unit x μm2) as a measurement of virus infection.
In Vivo assessment of PP242/HSV1-dICP0 combination
In order to assess the in vivo efficacy of PP242/HSV1 combination, 3x105 4T1 cells were
injected subcutaneously in the right flank of syngeneic mice. PP242 or vehicle was adminis-
tered by gavage at 60mg/kg at 10, 12, 14 and 17 days post-implantation. FLuc expressing
HSV1-dICP0 was intra-tumourally injected at 10 million pfu on days 11, 13 and 18. HSV1-
dICP0 spread was assessed by measuring luciferase activity using IVIS at day 14. Tumour size
was monitored using electronic caliper. End point at which animals were sacrificed was set to
tumour size 15mm X 15mm.
RNA extraction, quality control, reverse transcription, semi-quantitative
and qPCR
Adherent cells were lysed using Trizol reagent (Life Technologies) immediately in the plate.
RNA was isolated as per manufacturer’s instructions. RNA quality control and qPCR
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methodology was adopted from “the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments” (MIQE) guidelines [56, 57]. RNA purity was verified by nano-
drop and A260/A280 ratio for all samples used was between 1.8 and 2. RNA integrity was veri-
fied by denaturing TBE/agarose gels. An equal amount of total RNA per condition for IFNβ
level assessment following HSV1 stimulation were reverse transcribed into cDNA using Super-
Script III Reverse Transcriptase (Invitrogen) following manufacturer’s instructions. Random
Hexamer, RiboLock ribonuclease inhibitor and dNTPs were purchased from Thermo Scien-
tific. Transcripts abundance was determined by qPCR (eppendorf realplex 2) using iQ SYBR
Green Supermix from Bio-Rad following manufacturer’s instructions. qPCR and sqPCR prim-
ers were designed using the NCBI primer blast software (https://www.ncbi.nlm.nih.gov/tools/
primer-blast/) following MIQE guidelines for optimal primer length, GC content and Tm.
List of primers:
HSV1 gC Fwd: 5’-GCCAGATCGACACGCAGACG-3’
HSV1 gC Rev: 5’-CGAAATGGGCAGGGTGGACC-3’
HSV1 ICP4 Fwd: 5’-CGACACGGATCCACGACCC-3’
HSV1 ICP4 Rev: 5’-ATCCCCCTCCCGCGCTTCGTCCG-3’
HSV1 TK qPCR Fwd: 5’- TCGGGGACACGTTATTTACCCTG-3’
HSV1 TK qPCR Rev: 5’- GCCCAGGCAAACACGTTATACAG-3’
hβ-Actin Fwd: 5’-GGACTCCTATGTGGGTGACGAGG-3’
hβ-Actin Rev: 5’ -GGGAGAGCATAGCCCTCGTAGAT-3’
mβ-Actin qPCR Fwd: 5’-GTACCACCATGTACCCAGGC-3’
mβ-Actin qPCR Rev: 5’-CGCAGCTCAGTAACAGTCCG-3’
hIFNβ Fwd: 5’-AATTGAATGGGAGGCTTGAA-3’
hIFNβ Rev: 5’-AGCCAGGAGGTTCTCAACAA-3’
mIFNβ qPCR Fwd: 5’-CTCCAGCACTGGGTGGAATG-3’
mIFNβ qPCR Rev: 5’-AGTGGAGAGCAGTTGAGGAC-3’
mISG15 qPCR Fwd: 5’- TGGTACAGAACTGCAGCGAG-3’
mISG15 qPCR Rev: 5’- AGCCAGAACTGGTCTTCGTG-3’
mIRF7 qPCR Fwd: 5’- GCACTTTCTTCCGAGAACTGGAGG-3’
mIRF7 qPCR Rev: 5’- GTCTTGCCCAAAACCCAGGTA-3’
Fluc qPCR Fwd: 5’- ATCCGGAAGCGACCAACGCC-3’
Fluc qPCR Rev: 5’- GTCGGGAAGACCTGCCACGC-3’
Metabolic radiolabeling
Cells cultured in complete growth media were incubated for 30 min at 37˚C with complete cul-
ture medium containing 10 μCi/ml [35S]methionine. After 30 min incubation, cells were
washed with PBS twice and lysed in Laemmli sample buffer. Incorporation was measured by
TCA precipitation of proteins followed by scintillation counting. Radiolabeled proteins were
also separated by SDS-PAGE followed by autoradiography.
Polysome profile analysis
Sucrose density gradients (10 to 50%) were prepared using Biocomp Gradient Master 108 as
per manufacturer’s instructions and as previously published [58]. 10% and 50% sucrose solu-
tions were prepared in a buffer containing 20 mM HEPES-KOH pH 7.6, 100 mM KCl, 5 mM
MgCl2, 100 μg/ml cycloheximide, EDTA-free protease inhibitors mixture tablets (Roche), and
200 units/ml ribonuclease inhibitor (Ribolock from Thermo Fisher Scientific). A total of
7.5x106 cells for 4T1 and NMuMG and 15x106 for NT2196 were seeded per 15cm dish 24
hours prior to HSV1-dICP0 infection. Cells were pretreated for 30min with vehicle or PP242
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followed by infection with GFP-expressing HSV1-dICP0 at 0.1 MOI for 24 hours. Prior to
collection, cells were treated with 100μg/ml cycloheximide for 5 min at 37˚C, washed twice
with ice-cold PBS containing 100 μg/ml cycloheximide and collected by scraping. Cell pellet
following centrifugation at 1000 rpm for 10min at 4˚C were lysed in hypotonic lysis buffer
(5 mM Tris pH 7.5, 2.5 mM MgCl2, 1.5 mM KCl, EDTA-free protease inhibitors cocktail
tablets (Roche), 100 μg/ml cycloheximide, 2 mM DTT, 200 units/ml Ribolock, 0.5% (v/v)
Triton X-100, and 0.5% (w/v) sodium deoxycholate. Cell debris were cleared by centrifuga-
tion at 21,000g for 5 min at 4˚C. RNA concentration was determined using a Thermo Scien-
tific Nanodrop 2000 spectrophotometer. A total of 500 μg total RNA per condition were
loaded on each gradient, which were spun at 36,000 rpm (230501 X g) for 2 hours at 4˚C
using a Beckman coulter SW40Ti rotor and Optima L80 XP ultracentrifuge. Gradients were
fractionated using Teledyne ISCO fractionator with the pump set at 1.5ml per min. Optical
density at 254nm was recorded at 10 measurements per second frequency. RNA from each
fraction was isolated using TRIzol (Invitrogen) and treated with DNaseTurbo (Ambion)
according to the manufacturer’s instructions. Reverse transcription PCR (RT-PCR) and
quantitative RT-PCR (qRT-PCR) reactions were carried out using SuperScript III First-
Strand Synthesis System (Invitrogen) and iQ SYBR Green Supermix (BIO-RAD) according
to the manufacturer’s instructions. For qPCR experiments, each fraction was spiked with
5ng of polyA+ firefly luciferase mRNA (Promega) prior to extraction. Measurements were
then normalized to luciferase abundance, and plotted as relative transcript amount over
luciferase control.
Preparation of reporter mRNAs and luciferase reporter assay
Luciferase reporter mRNAs were generated using MAXIscript T7 in Vitro Transcription kit
(Ambion) according to the manufacturer’s protocol in the presence of the cap analog. PCR
products encoding a T7 promoter followed by luciferase and a poly(A) sequence were used as
templates for in vitro transcription. 4T1 cells were seeded on a 24-well-plate and cultured over-
night. Cells were transfected with capped HSV-ICP0-5’UTR-Rluc-pA, HSV-TK-5’UTR-Rluc-
pA, IRF7-5’UTR-Rluc-pA or Rluc-pA together with capped Fluc-pA as a transfection control
using Lipofectamine (Invitrogen). Cells were treated with 1μM PP242 for 24 hours and lysed
24 hours post transfection. Luciferase activities were determined using Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer’s instruction.
Statistical analyses
Statistical tests were performed within Prism (GraphPad) or Excel. Error bars for data pre-
sented are standard deviation (SD) from the mean. P values were calculated as follow: For
comparison between two independent groups, a two-tailed unpaired t test was used. For com-
parison between more than two independent groups, a one-way analysis of variance was per-
formed with Dunnett’s or Bonferroni’s post hoc tests, and adjusted p values were reported. p
values are reported as follows: , p< 0.05; , p< 0.01; , p< 0.001; ns denotes non-signifi-
cant p values.
Ethics statement
The animal experiment was performed in accordance with the guidelines for animal care at
the University of Ottawa Animal Care and Veterinary Services under the approved protocol
OGHRI-58. The University of Ottawa is a registered research facility under the Animals for
Research Act and is certified by the Canadian Council on Animal Care.
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Supporting information
S1 Fig. asTORi treatment enhances HSV1-dICP0 and g34.5-deleted HSV1-1716 infection
but limits the propagation of other oncolytic viruses. (A-C) U251N cells were pretreated
with DMSO (control), PP242 (2μM) or rapamycin (RAP 100nM) for 30 min and infected with
GFP-expressing HSV1-dICP0, GFP-expressing myxoma virus, or GFP-expressing VSVΔ51M at
a MOI of 0.1 in the presence of the inhibitors. Relative infection was monitored at different
time points post-infection by fluorescence microscopy (GFP-expressing HSV1-dICP0 (A) and
GFP-expressing myxoma virus (B)), or by Western blot (VSVΔ51M (C)). (D) Mouse mammary
carcinoma cell line 4T1 was pretreated with DMSO, rapamycin (100nM) or PP242 (2μM) for
30 min and infected with GFP-expressing HSV1-dICP0, GFP-expressing myxoma virus, GFP-
expressing vaccinia virus JX594, or GFP-expressing VSVΔ51M at a MOI of 0.1 in the presence
of the inhibitors. Relative infection was monitored 48 hours post-infection by fluorescence
microscopy. (E) The transformed NT2196 and non-transformed NMuMG cells were pre-
treated with DMSO or PP242 (2μM) for 30 min followed by infection with GFP-expressing
HSV1-dICP0 (left) or GFP-expressing g34.5-deleted HSV1-1716 (right), both viruses at a MOI
of 0.1. GFP fluorescence units measured using IncuCyte Zoom every 2 hours over a period of
48 hours are presented. Fluorescent and brightfield pictures are also included. (F) HSV1-
dICP0 titers at 48 hours post-infection obtained from the transformed 4T1 and NT2196 and
the non-transformed NMuMG cells when pretreated with DMSO, rapamycin (100nM), PP242
(2μM), or INK1341 (100nM). Results are presented as titers normalized to DMSO control set
at 100% ± SD (n = 3)).
(TIF)
S2 Fig. HSV1-dICP0 is potentiated in cancer cell lines by different asTORi. (A) Trans-
formed human cell lines HEK293T and HCT116 were pretreated with DMSO, PP242 (2μM),
INK1341 (100nM), or rapamycin (RAP 100nM) for 30 min and infected with GFP-expressing
HSV1-dICP0 at a MOI of 0.1 for 48 hours in the presence of the inhibitors. Viral protein
expression was monitored by Western blot using antibodies against HSV1 antigens; drug effi-
cacy was monitored by phosphorylation of rpS6 and 4E-BP1. Total rpS6 and β-actin expres-
sion were used as loading controls. (B) Huh7 malignant hepatocellular carcinoma cells were
pretreated with DMSO, PP242 (2μM) or INK1341 (100nM) for 30 min and infected with GFP-
expressing HSV1-dICP0 at a MOI of 0.1 in presence of the inhibitors. Cell oncolysis was moni-
tored by crystal violet staining of live cells 72 hours post-infection (C) Transformed 4T1 and
NT2196, and non-transformed NMuMG cells were infected with GFP-expressing HSV1-
dICP0 in the presence of DMSO, PP242 (2μM), INK128 (100nM), or Torin1 (100nM), pre-
treated for 30 min prior to infection. In this particular experiment, 4T1 and NT2196 cells were
infected at a MOI of 0.1 while the NMuMG cells were infected at a MOI of 1. Virus infection
was assessed 48 hours post-infection by fluorescence microscopy. (D) Non-transformed cell
lines SHEP and NMuMG were pretreated as in (A) and infected with GFP-expressing
HSV1-dICP0 at a MOI of 0.1 for 48 hours. Viral protein expression was monitored by Western
blot. (E) ImageJ quantification of the percentage of GFP positive cells following infection of
4T1, NMuMG or NT2196 in presence of DMSO, PP242 (2μM) or INK1341 (100nM). Results
are presented as total percentage of GFP positive cells ± SD (n = 3).
(TIF)
S3 Fig. asTORi treatment reduces HSV1-induced type-I IFN responses in normal and can-
cer cells. (A) Non-transformed mouse embryonic fibroblasts (MEFs) or the human glioma
cell line U251N were infected with wild type HSV1 in the presence of DMSO, rapamycin
(100nM) or PP242 (2μM). Ifn-β mRNA levels were measured 24 hours post-infection by
mTOR inhibition and HSV1-dICP0
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RT-PCR. (B) Graphical representation of type-I IFN protection assay shown in Fig 3C: Type-I
IFN production was induced by transfecting cells with poly(I:C) RNA in the presence of
DMSO, rapamycin, or PP242, and incubated overnight. The supernatant containing secreted
type-I IFN was used to condition naïve cells for 6 hours followed by wild type HSV1 infection.
Infected cells were lysed 24 hours post-infection for analysis by Western blot and virus titra-
tion. (C) HEKBLUE assays performed on normal HFF cell line and glioblastoma cell lines
U343 and U373 treated for 6 hours with poly(I:C) in presence of DMSO, Rapamycin (RAP
100nM), PP242 (2μM), or Torin1 (100nM). Quanti BLUE type I IFN detection was assessed by
the levels of secreted alkaline phosphatase and measure by OD at 650nM. UV absorbance pro-
files (254nm) of ribosomes isolated from 4T1 cells (D) and NT2196 cells (F) pretreated with
DMSO or PP242 (2μM) for 30 min prior to infection with HSV1-dICP0 at a MOI of 0.1 for 24
hours. 40S, 60S, and 80S denote the corresponding ribosomal subunits and monosomes,
respectively. Western blotting performed at 48 hours during the same experiment showing an
increase in HSV1-dICP0 protein synthesis. (E) Total amount and polysome distribution of β-
actin, Irf7, gC and ICP4 mRNAs from DMSO- or PP242-treated and infected 4T1 cells was
determined by semi-quantitative RT-PCR (sqRT-PCR). (G) Polysome distribution of β-actin,
Irf7, Isg15 and TK mRNAs from the fractions of DMSO- or PP242-treated and infected
NT2196 cells was determined by quantitative RT-PCR (qRT-PCR) and presented as relative
transcript amount in each fraction normalized to spiked luciferase mRNA control. (H) Lucif-
erase reporter constructs containing the 5’ UTR of ICP0, TK, or Irf7 were in vitro transcribed
and transfected into 4T1 cells. Renilla luciferase over Firefly luciferase was measured by Lumi-
glo and presented as % PP242 treated over DMSO samples.
(TIF)
S4 Fig. eIF4E/4E-BP expression and the effect of asTORi on HSV1-dICP0 infection. (A)
RT-qPCR measurements of the levels of immediate-early HSV1 gene ICP4 at 8 hours post-
infection with HSV1-dICP0 at 0.1MOI in 4T1, NMuMG and NT2196 cell lines pretreated
with DMSO or INK1341 (100nM) for 30 min prior to infection. Results are presented as total
transcript levels normalized to DMSO control set to 1 ± SD (n = 3). (B) Global protein synthe-
sis was assessed by a 30 min pulse [35S]methionine incorporation into newly synthesized pro-
teins at 24 hours post-infection with wild-type HSV1 at a MOI of 1. Proteins were separated
on SDS-PAGE and changes in protein synthesis revealed by autoradiography (left panels).
Corresponding Western blot for HSV1 proteins in infected cells treated or not with mTOR
inhibitors (right panels). (C) 786–0, 4T1 and NT2196 cells were exposed to elevated concentra-
tions of the asTORi PP242 or INK1341, and infected with GFP-expressing HSV1-dICP0 at a
MOI of 0.1 for 48 hours. Resulting virus infection was assessed by fluorescence microscopy.
(D) Normal murine mammary epithelial cell line NMuMG and NT2196 transformed mam-
mary cells were treated with increasing concentrations of the asTORi PP242 and infected
with HSV1-dICP0 at a MOI of 0.1. Cell lysates were prepared at 48 hours post-infection and
assessed by Western Blotting for HSV1, p-4E-BP1 (T37/46; S65; T70), total 4E-BP1 and β-
actin (loading control). Note that different exposure time between NMuMG and NT2196 are
presented for the HSV1 blot to demonstrate the repression of HSV1-dICP0 in NMuMG cells,
versus the augmentation of HSV1-dICP0 protein expression in NT2196 cells. (E) Transformed
4T1 and NT2196 and non-transformed NMuMG cells were pretreated with PP242 (2μM) for
30 min and infected with HSV1-dICP0 at 0.1 MOI in the presence of the inhibitor. At 48
hours post-infection, viral proteins, and eIF4E and 4E-BP1/2/3 protein levels were monitored
by Western Blot. β-actin expression was used as loading control. (F) Transformed 4T1 and
NT2196 and non-transformed NMuMG were transduced to stably express shRNA against
4E-BP2, or scrambled shRNA control. Transduced cells were infected as above with GFP-
mTOR inhibition and HSV1-dICP0
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007264 August 23, 2018 18 / 23
expressing HSV1-dICP0 at 0.1 MOI in the presence of DMSO, PP242 (2μM), or INK1341
(100nM). At 48 hours post-infection, GFP fluorescence was monitored by fluorescence
microscopy.
(TIF)
S5 Fig. asTORi effect on HSV1 is dependent on eIF4E/4E-BP expression. (A-C) Non-trans-
formed NIH3T3 and SHEP cells, and (D-H) transformed U251N glioma cell line were trans-
duced to stably overexpress eIF4E, 4E-BP1, or control empty pBabe vector (A-C, F-H), or to
stably express shRNA against eIF4E or scrambled control (D,E). Transduced cells were
infected with GFP-expressing HSV1-dICP0 at 0.1 MOI in the presence of DMSO, PP242
(2μM) or INK1341 (100nM), pretreated for 30 min prior to infection. HSV1 proteins were
assessed by Western blot (A-D, F-G), and viral infection was monitored by fluorescence
microscopy (E,H).
(TIF)
S6 Fig. Schema of HSV1-dICP0 infection of cells in presence of active-site mTOR inhibi-
tors (asTORi). asTORi treatment results in a strong decrease in antiviral gene transcription
and translation, but HSV1-dICP0 viral protein synthesis differs: Depicted on the left, normal
cells with homeostatic eIF4E/4E-BP expression, or cells with either reduced eIF4E or elevated
4E-BP1 expression, asTORi treatment potently limits viral and host protein synthesis, resulting
in limited infection and spread of the virus. Depicted in the middle, in the absence of asTORi,
cellular antiviral gene transcription and translation is normally induced and controls HSV1-
dICP0 propagation. Finally, depicted on the right, elevated eIF4E expression or loss of 4E-BPs
in cancer cells, or cells genetically modified to overexpress eIF4E or silence 4E-BP1/2, sustain
sufficient protein synthesis levels in presence of asTORi to favor HSV1-dICP0 mRNA transla-
tion while the antiviral response is limited.
(TIF)
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